Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Greenslopes, Australia Clinical Trials

A listing of Greenslopes, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (36) clinical trials

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

In the dose-escalation phase, escalating doses of AB928 in combination with AB122 will be assessed in participants with advanced malignancies. Eligible participants will receive oral administration of AB928 as well as IV infusion of AB122. The recommended dose for expansion (RDE) of AB928 will be determined upon completion of the …

Phase

0.35 miles

Learn More »

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301 (cosibelimab), a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months of visits with survival follow-up for select cohorts). …

Phase

0.35 miles

Learn More »

MultiPulse Therapy (MPT) for AF

A prospective nonrandomized feasibility study involving acute testing of MPT in subjects with paroxysmal and persistent AF during clinically indicated atrial fibrillation catheter ablation procedure. Subjects will be split into 2 cohorts depending on status at time of procedure. In Atrial Fibrillation at time of procedure (Clinical AF) In Normal …

Phase

0.35 miles

Learn More »

Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consists of 2 parts. Part 1 is a JNJ-61186372 Monotherapy and Combination Dose Escalations and Part 2 JNJ-61186372 Monotherapy and Combination Dose Expansions. In Part 1, participants with evaluable NSCLC …

Phase

1.88 miles

Learn More »

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Cisplatin is a widely used and effective chemotherapy in the treatment of adult and pediatric solid tumors, including bladder, testicular, head and neck, and lung cancers. Serious side effects of cisplatin treatment include ototoxicity. To date, no approved therapy to prevent or treat ototoxicity exists for people receiving cisplatin treatment, …

Phase

1.88 miles

Learn More »

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-nave higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase

1.88 miles

Learn More »

Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies

This open label Phase 1 multicenter study is designed to evaluate the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SAR442720 in combination with pembrolizumab in participants with solid tumors. The expected duration of study intervention for participants may vary, based on progression date; median …

Phase

1.88 miles

Learn More »

A Multi-center Randomized Double-blind Placebo-controlled Multiple Ascending Dose Study of the Safety Tolerability and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

The study is designed as a MAD escalation in up to 3 cohorts of patients, followed by a cohort expansion to further confirm the safety and tolerability of the selected dose, prior to further investigation in Phase 2 studies. The cohort expansion will also support the assessment of the trial's …

Phase

1.88 miles

Learn More »

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

All patients will receive sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks until occurrence of PD, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor. There will be 9 cohorts in the study. Approximately 20 patients will be enrolled …

Phase

2.84 miles

Learn More »

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

This is a Phase I, open-label, dose escalation and dose expansion study with BID (suspension) and TID (tablet) oral dose of tazemetostat. Subjects will be screened for eligibility within 14 days of the planned first dose of tazemetostat. A treatment cycle will be 28 days. Response assessment will be evaluated …

Phase

2.84 miles

Learn More »